Amgen Inc. Increase (Decrease) in Other Accrued Liabilities
Amgen Inc. (AMGN) reported Increase (Decrease) in Other Accrued Liabilities of $782.00 million for the 9-month period ending 2011-09-30, per its 10-Q filed 2011-11-04.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccruedLiabilities · last filed 2011-11-04
- Amgen Inc. increase (decrease) in other accrued liabilities for the quarter ending 2011-09-30 was $817.00M, a 184.67% increase year-over-year.
- Amgen Inc. increase (decrease) in other accrued liabilities for the quarter ending 2011-06-30 was $73.00M, a 48.95% decline year-over-year.
- Amgen Inc. increase (decrease) in other accrued liabilities for the quarter ending 2011-03-31 was -$108.00M.
- Amgen Inc. increase (decrease) in other accrued liabilities for the quarter ending 2010-12-31 was $241.00M, a 31.73% decline year-over-year.
- Amgen Inc. increase (decrease) in other accrued liabilities for fiscal 2010 was $152.00M, a 52.50% decline from fiscal 2009.
- Amgen Inc. increase (decrease) in other accrued liabilities for fiscal 2009 was $320.00M.
- Amgen Inc. increase (decrease) in other accrued liabilities for fiscal 2008 was -$30.00M, a 104.36% decline from fiscal 2007.
- Amgen Inc. increase (decrease) in other accrued liabilities for fiscal 2007 was $688.00M.
| Period end | Increase (Decrease) in Other Accrued Liabilities 3 month | Increase (Decrease) in Other Accrued Liabilities 6 month | Increase (Decrease) in Other Accrued Liabilities 6 month as first filed | Increase (Decrease) in Other Accrued Liabilities 9 month | Increase (Decrease) in Other Accrued Liabilities 9 month as first filed | Increase (Decrease) in Other Accrued Liabilities 12 month |
|---|---|---|---|---|---|---|
| 2011-09-30 | $817.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $890.00M derived: sum of 2 quarters · filed 2011-11-04 | $782.00M 10-Q · filed 2011-11-04 | $1.02B derived: sum of 4 quarters · filed 2011-11-04 | ||
| 2011-06-30 | $73.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-08 | -$35.00M 10-Q · filed 2011-08-08 | $206.00M derived: sum of 3 quarters · filed 2011-08-08 | $493.00M derived: sum of 4 quarters · filed 2011-11-04 | ||
| 2011-03-31 | -$108.00M 10-Q · filed 2011-05-10 | $133.00M derived: sum of 2 quarters · filed 2011-05-10 | $420.00M derived: sum of 3 quarters · filed 2011-11-04 | $563.00M derived: sum of 4 quarters · filed 2011-11-04 | ||
| 2010-12-31 | $241.00M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-25 | $528.00M derived: sum of 2 quarters · filed 2011-11-04 | $671.00M derived: sum of 3 quarters · filed 2011-11-04 | $152.00M 10-K · filed 2011-02-25 | ||
| 2010-09-30 | $287.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $430.00M derived: sum of 2 quarters · filed 2011-11-04 | -$89.00M 10-Q · filed 2011-11-04 | $264.00M derived: sum of 4 quarters · filed 2011-11-04 | ||
| 2010-06-30 | $143.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-08 | -$376.00M 10-Q · filed 2011-08-08 | -$23.00M derived: sum of 3 quarters · filed 2011-08-08 | $311.00M derived: sum of 4 quarters · filed 2011-08-08 | ||
| 2010-03-31 | -$519.00M 10-Q · filed 2011-05-10 | -$166.00M derived: sum of 2 quarters · filed 2011-05-10 | $168.00M derived: sum of 3 quarters · filed 2011-05-10 | $470.00M derived: sum of 4 quarters · filed 2011-05-10 | ||
| 2009-12-31 | $353.00M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-25 | $687.00M derived: sum of 2 quarters · filed 2011-02-25 | $989.00M derived: sum of 3 quarters · filed 2011-02-25 | $320.00M 10-K · filed 2011-02-25 | ||
| 2009-09-30 | $334.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-08 | $636.00M derived: sum of 2 quarters · filed 2010-11-08 | -$33.00M 10-Q · filed 2010-11-08 | -$66.00M 10-Q · filed 2009-11-06 | $62.00M derived: sum of 4 quarters · filed 2011-02-25 | |
| 2009-06-30 | $302.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2010-08-09 | -$367.00M 10-Q · filed 2010-08-09 | -$355.00M 10-Q · filed 2009-08-10 | -$272.00M derived: sum of 3 quarters · filed 2011-02-25 | -$502.00M derived: sum of 4 quarters · filed 2011-02-25 | |
| 2009-03-31 | -$669.00M 10-Q · filed 2010-05-07 | -$574.00M derived: sum of 2 quarters · filed 2011-02-25 | -$804.00M derived: sum of 3 quarters · filed 2011-02-25 | |||
| 2008-12-31 | $95.00M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-25 | -$135.00M derived: sum of 2 quarters · filed 2011-02-25 | -$30.00M 10-K · filed 2011-02-25 | |||
| 2008-09-30 | -$230.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2009-11-06 | -$125.00M 10-Q · filed 2009-11-06 | ||||
| 2008-06-30 | $105.00M 10-Q · filed 2009-08-10 | |||||
| 2007-12-31 | $688.00M 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |